Search results
Results from the WOW.Com Content Network
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
2017: The FDA approved Parsabiv in February [73] and Mvasi (bevacizumab-awwb) in September. [74] 2018:Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July. [75] 2019: In January, Evenity (romosozumab) received approval in Japan, [76] [77] followed by FDA approval in April. [78]
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
The FDA reviewed 25 cases between July 2010 through May 2021 during the investigation. ... approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at ...
Use in pregnancy is known to harm the baby. [3] Bendamustine is in the alkylating agents family of medication. [3] It works by interfering with the function of DNA and RNA. [3] Bendamustine was approved for medical use in the United States in 2008. [3] It is on the World Health Organization's List of Essential Medicines.
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Idecabtagene vicleucel was approved for medical use in the United States in March 2021. [4] [7] It is the first cell-based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma. [4] [7] It was approved for medical use in the European Union in August 2021. [5] [9]